DORIDEN Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Doriden, and when can generic versions of Doriden launch?
Doriden is a drug marketed by Sanofi Aventis Us and is included in one NDA.
The generic ingredient in DORIDEN is glutethimide. There are four drug master file entries for this compound. Additional details are available on the glutethimide profile page.
Summary for DORIDEN
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 25 |
Patent Applications: | 3,269 |
Formulation / Manufacturing: | see details |
DailyMed Link: | DORIDEN at DailyMed |
Anatomical Therapeutic Chemical (ATC) Classes for DORIDEN
US Patents and Regulatory Information for DORIDEN
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sanofi Aventis Us | DORIDEN | glutethimide | CAPSULE;ORAL | 009519-008 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Sanofi Aventis Us | DORIDEN | glutethimide | TABLET;ORAL | 009519-002 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Sanofi Aventis Us | DORIDEN | glutethimide | TABLET;ORAL | 009519-005 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |